Erasca(ERAS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Erasca Reports First Quarter 2024 Business Updates and Financial Results Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma SAN DIEGO, May 8, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fi ...